Are proton pump inhibitors close or distant relatives? (Lecture)
DOI: 10.32364/2587-6821-2021-5-6-398-403
S.V. Plyusnin
Non-State Educational Private Institution Of Additional Professional Education
"Medical Dental Institute", Moscow, Russian Federation
Proton pump inhibitors (PPIs) are drugs that block H+-K+-ATPase on the apical membrane of the gastric parietal cells. Due to this pharmacological effect, it is possible to achieve inhibition of hydrochloric acid and its secretion formation. To date, 6 PPIs (under an international nonproprietary name) have been registered in the Russian Federation. PPIs, having proven efficacy and safety in many clinical studies, have several patterns reflected in their patient information leaflet. The attending physician should pay attention to these patterns before starting PPIs therapy. The author considers the characteristics of pharmacokinetics, pharmacodynamics of various PPIs, as well as the issues concerning efficacy and safety of use. The lecture also discusses the adverse events of PPIs, including rare ones, such as mental disorders (hallucinations), bronchospasm, subacute cutaneous lupus erythematosus. The author focuses on the metabolism peculiarities of various PPIs and the possibility of adverse drug interactions. It is especially important to consider the PPIs administration in the treatment of elderly and senile patients, patients with liver failure, during the eradication of Helicobacter pylori.
Keywords: proton pump inhibitors, patient information leaflet, adverse events, eradication, Helicobacter pylori.
For citation: Plyusnin S.V. Are proton pump inhibitors close or distant relatives? (Lecture). Russian Medical Inquiry. 2021;5(6):398–403 (in Russ.). DOI: 10.32364/2587-6821-2021-5-6-398-403.
About the author:
Sergey V. Plyusnin — Dr. Sc. (Med.), Professor, Honored Doctor of the Russian Federation, Head of the Department of Therapy, Non-State Educational Private Institution Of Additional Professional Education "Medical Dental Institute"; 9/1, Pskovskaya str., Moscow, 127253, Russian Federation; ORCID iD 0000-0002-4885-8976.
Contact information: Sergey V. Plyusnin, e-mail: plsv@mail.ru.
Financial Disclosure: the author has not a financial or property interest in any material or method mentioned.
There is no conflict of interests.
Received 07.07.2021.
Revised 30.07.2021.
Accepted 24.08.2021.
2. Kirchheimer J., Glatt S., Fuhr U. et al. Relative potency of protonpumpinhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009;65:19–31.
3. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999;13(Suppl 3):27–36. DOI: 10.1046/j.1365-2036.1999.00022.x.
4. Омез®. (Электронный ресурс.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%u043e%u043c%u0435%u0437andOwnerName=andMnfOrg=andMnfOrgCountry=andisfs=0andisND=-1andregtype=1%2c6andpageSize=10andorder=RegDateandorderType=descandpageNum=1 (дата обращения: 11.06.2021). [Omez®. (Electronic resource.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%u043e%u043c%u0435%u0437andOwnerName=andMnfOrg=andMnfOrgCountry=andDisfs-10reg and amp; RegDate and orderType = desc and pageNum = 1 (access date: 11.06.2021) (in Russ.)].
5. Нольпаза®. (Электронный ресурс.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%d0%9d%d0%be%d0%bb%d1%8c%d0%bf%d0%b0%d0%b7%d0%b0andOwnerName=andMnfOrg=andMnfOrgCountry=andisfs=0andisND=-1andregtype=1%2c6andpageSize=10andorder=RegDateandorderType=descandpageNum=1 (дата обращения: 11.06.2021). [Nolpaza®. (Electronic resource.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%d0%9d%d0%be%d0%bb%d1%8c%d0%bf%d0%b0%d0 % b7% d0% b0 and OwnerName = and MnfOrg = and MnfOrgCountry = and isfs = 0 and isND = -1 and regtype = 1% 2c6 and pageSize = 10 and order = RegDate and orderType = desc and pageNum = 1 (access date: 11.06.2021) (in Russ.)].
6. Разо®. (Электронный ресурс.) URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4c6f0da-6f4d-4251-ad9b-f7dfe6ccd125andt= (дата обращения: 11.06.2021). [Razo®. (Electronic resource.) URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=e4c6f0da-6f4d-4251-ad9b-f7dfe6ccd125andt= (access date: 11.06.2021) (in Russ.)].
7. Париет®. (Электронный ресурс.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%u043f%u0430%u0440%u0438%u0435%u0442andOwnerName=andMnfOrg=andMnfOrgCountry=andisfs=0andisND=-1andregtype=1%2c6andpageSize=10andorder=RegDateandorderType=descandpageNum=1 (дата обращения: 11.06.2021). [Pariet. (Electronic resource.) URL: https://grls.rosminzdrav.ru/GRLS.aspx?RegNumber=andMnnR=andlf=andTradeNmR=%u043f%u0430%u0440%u0438%u0435%u0442andOwnerName=andMnfOrg=andMnfOregrgCount=andMnfOrg=andMnfOisfrgCount=andMnfOrg=andMnfOregrgCount=1= 2c6 and pageSize = 10 and order = RegDate and orderType = desc and pageNum = 1 (access date: 11.06.2021) (in Russ.)].
8. Sebastián Domingo J.J. Omeprazole-induced hallucinations. Not as rare as you might think. Gastroenterol Hepatol. 2018;41(4):266–267. DOI: 10.1016/j.gastrohep.2017.05.002.
9. Razdan A., Viswanathan R., Tusher A. Pantoprazole-Induced Delirium: Review of a Case and Associated Literature. Case Rep Psychiatry. 2018;2018:1232535. DOI: 10.1155/2018/1232535.
10. Sarosiek I., Olyaee M., Majewski M. et al. Significant Increase of Esophageal Mucin Secretion in Patients with Reflux Esophagitis After Healing with Rabeprazole: Its Esophagoprotective Potential Dig Dis Sci. 2009;54:2137–2142. DOI: 10.1007/s10620-008-0589-z.
11. Skoczylas T. Significant enhancement of gastric mucin content after rabeprazole administration: its potential clinical significance in acid related disorders. Dig. Dis. Sci. 2003;48:322–328.
12. Petrillo A., Smyth E.C. 27 years of stomach cancer: painting a global picture. Lancet Gastroenterol Hepatol. 2020;5(1):5–6. DOI: 10.1016/S2468-1253(19)30357-7.
13. Wang Z., Shaheen N.J., Whiteman D.C. et al. Helicobacter pylori Infection Is Associated With Reduced Risk of Barrett's Esophagus: An Analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Am J Gastroenterol. 2018;113(8):1148–1155. DOI: 10.1038/s41395-018-0070-3.
14. GBD 2017 Stomach Cancer Collaborators. The global, regional, and national burden of stomach cancer in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020 Jan;5(1):42–54. DOI: 10.1016/S2468-1253(19)30328-0.
15. Blaser M.J., Chen Y., Reibman J. Does Helicobacter pylori protect against asthma and allergy? Gut. 2008 May;57(5):561–567. DOI: 10.1136/gut.2007.133462.
16. Язвенная болезнь. Клинические рекомендации. (Электронный ресурс.) URL: https://cr.minzdrav.gov.ru/recomend/277_1 (дата обращения: 11.06.2021). [Peptic ulcer. Clinical guidelines. (Electronic resource.) URL: https://cr.minzdrav.gov.ru/recomend/277_1 (access date: 11.06.2021) (in Russ.)].
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Распечатать